For: | Marchesi I, Bagella L. Targeting Enhancer of Zeste Homolog 2 as a promising strategy for cancer treatment. World J Clin Oncol 2016; 7(2): 135-148 [PMID: 27081636 DOI: 10.5306/wjco.v7.i2.135] |
---|---|
URL: | https://www.wjgnet.com/2218-4333/full/v7/i2/135.htm |
Number | Citing Articles |
1 |
Yating Xu, Xiao Yu, Zongzong Sun, Yuting He, Wenzhi Guo. Roles of lncRNAs Mediating Wnt/β-Catenin Signaling in HCC. Frontiers in Oncology 2022; 12 doi: 10.3389/fonc.2022.831366
|
2 |
Alexius John, Hazel O’Sullivan, Sanjay Popat. Updates in Management of Malignant Pleural Mesothelioma. Current Treatment Options in Oncology 2023; 24(12): 1758 doi: 10.1007/s11864-023-01148-2
|
3 |
Chidinma Ejikeme, Zeenat Safdar. Exploring the pathogenesis of pulmonary vascular disease. Frontiers in Medicine 2024; 11 doi: 10.3389/fmed.2024.1402639
|
4 |
Komal Thapa, Heena Khan, Amarjot Kaur Grewal, Neha Kanojia, Gagandeep Kaur, Parul Sood, Thakur Gurjeet Singh. Insights into the Therapeutic Potential of Phytoconstituents as an Epigenetic Modulators in Diabetic Nephropathy. Current Pharmacology Reports 2023; 9(6): 404 doi: 10.1007/s40495-023-00345-9
|
5 |
Jian Wang, Bo Yang, Yingzhao Wang, Shuhan Liu, Changkai Ma, Jianmin Piao, Shiqiang Ma, Dehai Yu, Wei Wu. CBX2 enhances the progression and TMZ chemoresistance of glioma via EZH2-mediated epigenetic silencing of PTEN expression. Frontiers in Pharmacology 2024; 15 doi: 10.3389/fphar.2024.1430891
|
6 |
Hanif Khan, Zhengzhong Ni, Hai Feng, Yaqi Xing, Xuejun Wu, Danmei Huang, Ling Chen, Yongdong Niu, Ganggang Shi. Combination of curcumin with N-n-butyl haloperidol iodide inhibits hepatocellular carcinoma malignant proliferation by downregulating enhancer of zeste homolog 2 (EZH2) - lncRNA H19 to silence Wnt/β-catenin signaling. Phytomedicine 2021; 91: 153706 doi: 10.1016/j.phymed.2021.153706
|
7 |
Firdous Fatima, Nikhil Kumar Chourasiya, Mitali Mishra, Shivam Kori, Sandhya Pathak, Ratnesh Das, Varsha Kashaw, Arun K. Iyer, Sushil Kumar Kashaw. Curcumin and its Derivatives Targeting Multiple Signaling Pathways
to Elicit Anticancer Activity: A Comprehensive Perspective. Current Medicinal Chemistry 2024; 31(24): 3668 doi: 10.2174/0929867330666230522144312
|
8 |
Ioannis Anestopoulos, Aristeidis Sfakianos, Rodrigo Franco, Katerina Chlichlia, Mihalis Panayiotidis, David Kroll, Aglaia Pappa. A Novel Role of Silibinin as a Putative Epigenetic Modulator in Human Prostate Carcinoma. Molecules 2016; 22(1): 62 doi: 10.3390/molecules22010062
|
9 |
Irene Marchesi, Luca Sanna, Milena Fais, Francesco P. Fiorentino, Antonio Giordano, Luigi Bagella. 12‐O‐tetradecanoylphorbol‐13‐acetate and EZH2 inhibition: A novel approach for promoting myogenic differentiation in embryonal rhabdomyosarcoma cells. Journal of Cellular Physiology 2018; 233(3): 2360 doi: 10.1002/jcp.26107
|
10 |
Chidimma Agatha Akpa, Karsten Kleo, Elisabeth Oker, Nancy Tomaszewski, Clemens Messerschmidt, Cristina López, Rabea Wagener, Kathrin Oehl-Huber, Katja Dettmer, Anne Schoeler, Dido Lenze, Peter J. Oefner, Dieter Beule, Reiner Siebert, David Capper, Lora Dimitrova, Michael Hummel. Acquired resistance to DZNep-mediated apoptosis is associated with copy number gains of AHCY in a B-cell lymphoma model. BMC Cancer 2020; 20(1) doi: 10.1186/s12885-020-06937-8
|
11 |
Zijian Ma, Haifei Niu, Haiqi Qi, Yan Li. Functional role of lncRNA MEG3 on pyroptosis through interacting with EZH2 and YTHDC1 in postoperative cognitive dysfunction. Brain Research Bulletin 2024; 217: 111060 doi: 10.1016/j.brainresbull.2024.111060
|
12 |
Yi Zhang, Bo Tang, Jun Song, Shuiping Yu, Yang Li, Huizhao Su, Songqing He. Lnc-PDZD7 contributes to stemness properties and chemosensitivity in hepatocellular carcinoma through EZH2-mediated ATOH8 transcriptional repression. Journal of Experimental & Clinical Cancer Research 2019; 38(1) doi: 10.1186/s13046-019-1106-2
|
13 |
Luca Sanna, Irene Marchesi, Mariarosa A. B. Melone, Luigi Bagella. The role of enhancer of zeste homolog 2: From viral epigenetics to the carcinogenesis of hepatocellular carcinoma. Journal of Cellular Physiology 2018; 233(9): 6508 doi: 10.1002/jcp.26545
|
14 |
Francesco Paolo Fiorentino, Irene Marchesi, Christoph Schröder, Ronny Schmidt, Jun Yokota, Luigi Bagella. BET-Inhibitor I-BET762 and PARP-Inhibitor Talazoparib Synergy in Small Cell Lung Cancer Cells. International Journal of Molecular Sciences 2020; 21(24): 9595 doi: 10.3390/ijms21249595
|
15 |
Mohammad Ghanbari, Negin Sadi Khosroshahi, Maryam Alamdar, Adel Abdi, Aida Aghazadeh, Mohammad Ali Hosseinpour Feizi, Mehdi Haghi. An Updated Review on the Significance of DNA and Protein
Methyltransferases and De-methylases in Human Diseases: From
Molecular Mechanism to Novel Therapeutic Approaches. Current Medicinal Chemistry 2024; 31(23): 3550 doi: 10.2174/0929867330666230607124803
|
16 |
Imlimaong Aier, Pritish Kumar Varadwaj, Utkarsh Raj. Structural insights into conformational stability of both wild-type and mutant EZH2 receptor. Scientific Reports 2016; 6(1) doi: 10.1038/srep34984
|
17 |
Chidimma Agatha Akpa, Karsten Kleo, Dido Lenze, Elisabeth Oker, Lora Dimitrova, Michael Hummel, Francesco Bertolini. DZNep-mediated apoptosis in B-cell lymphoma is independent of the lymphoma type, EZH2 mutation status and MYC, BCL2 or BCL6 translocations. PLOS ONE 2019; 14(8): e0220681 doi: 10.1371/journal.pone.0220681
|
18 |
Arnaud Scherpereel, Frederic Wallyn, Steven M Albelda, Camille Munck. Novel therapies for malignant pleural mesothelioma. The Lancet Oncology 2018; 19(3): e161 doi: 10.1016/S1470-2045(18)30100-1
|
19 |
Arnaud Scherpereel. Chemotherapy for Malignant Pleural Mesothelioma: Past, Present and Future. Current Pulmonology Reports 2017; 6(2): 155 doi: 10.1007/s13665-017-0179-7
|
20 |
Fabio Nicolini, Martine Bocchini, Giuseppe Bronte, Angelo Delmonte, Massimo Guidoboni, Lucio Crinò, Massimiliano Mazza. Malignant Pleural Mesothelioma: State-of-the-Art on Current Therapies and Promises for the Future. Frontiers in Oncology 2020; 9 doi: 10.3389/fonc.2019.01519
|
21 |
Duo Xu, Haitang Yang, Ralph A. Schmid, Ren-Wang Peng. Therapeutic Landscape of Malignant Pleural Mesothelioma: Collateral Vulnerabilities and Evolutionary Dependencies in the Spotlight. Frontiers in Oncology 2020; 10 doi: 10.3389/fonc.2020.579464
|
22 |
Stefano Zoroddu, Angela Lucariello, Antonio De Luca, Luigi Bagella. Dysregulation of miRNAs in Soft Tissue Sarcomas. Cells 2024; 13(22): 1853 doi: 10.3390/cells13221853
|
23 |
Ying Cheng, Ying Li, Xin Huang, Wenbin Wei, Yi Qu. Expression of EZH2 in uveal melanomas patients and associations with prognosis. Oncotarget 2017; 8(44): 76423 doi: 10.18632/oncotarget.19462
|
24 |
Lilong Xia, Xinhai Zhu, Lei Zhang, Yanhui Xu, Guoping Chen, Jing Luo. EZH2 enhances expression of CCL5 to promote recruitment of macrophages and invasion in lung cancer. Biotechnology and Applied Biochemistry 2020; 67(6): 1011 doi: 10.1002/bab.1875
|
25 |
Serena Ferraresso, Arianna Aricò, Tiziana Sanavia, Silvia Da Ros, Massimo Milan, Luciano Cascione, Stefano Comazzi, Valeria Martini, Mery Giantin, Barbara Di Camillo, Sandro Mazzariol, Diana Giannuzzi, Laura Marconato, Luca Aresu. DNA methylation profiling reveals common signatures of tumorigenesis and defines epigenetic prognostic subtypes of canine Diffuse Large B-cell Lymphoma. Scientific Reports 2017; 7(1) doi: 10.1038/s41598-017-11724-w
|
26 |
A. Scherpereel. Traitement du mésothéliome pleural malin en 2016. Revue des Maladies Respiratoires Actualités 2016; 8(5): 445 doi: 10.1016/S1877-1203(16)30135-5
|